Detection is the Key to Success
About MycoMed Technologies
MycoMed is focused on development and commercialization of products to enable early detection and prevention of fungal infections.
Much progress in medicine is accompanied by risks for infections, caused by weakening of natural defenses in the immune system. People who receive organ transplantation, cancer therapy and medications to suppress the immune system have risks for infections caused by fungi. These organisms are everywhere in our environment and infections are difficult to treat. Prevention is a key step to improving outcomes. Our first product, a urine test to detect fungal infections in the lung, is in clinical studies now.
Mycomed Technologies is located in the Johns Hopkins Fast Forward Accelerator in Baltimore, Maryland. This organization has been operating since 2014.
Company Announcements
April
The MycoMed team will give an oral presentation on Characterisation of mAb476-reactive galactofuranose-bearing Aspergillus antigens excreted in urine, to be presented April, 2019 at 29th European Congress of Clinical Microbiology and Infectious Diseases 2019; Amsterdam, Netherlands
April
The MycoMed team will give an oral presentation on Development and evaluation of a rapid urine diagnostic test for pulmonary aspergillosis, to be presented April 21, 2018 at 28th European Congress of Clinical Microbiology and Infectious Diseases 2018; Madrid Spain
February
Hopkins and MycoMed team presents poster on Urine Antigen Detection as an Aid to Diagnose Invasive Aspergillosis, presented Feb 3, 2018 at 8th Advances Against Aspergillus 2018; Lisbon Portugal
Download the Poster
July
MycoMed Technologies announces receipt of NIH Phase II STTR to support clinical development of urine aspergillosis diagnostic test, MycoFlow-Asp™
June
Hopkins team and MycoMed Technologies presents proof-of-concept data at the American Society of Microbiology (ASM) meeting in New Orleans, June 2-4
May
MycoMed Technologies partners with the NIH-supported AsTeC repository to test urine diagnostic assay
April
MycoMed Technologies moves to the Johns Hopkins Fast Forward Accelerator
MycoMed Technologies partners with BioAssay Works to develop the urine diagnostic assay, MycoFlow-Asp™
Dr. Bradley Spellberg joins as a MycoMed Technologies director
MycoMed Technologies wins Maryland Innovation Initiative (MIII) phase III grant from TEDCO
MycoMed Technologies wins Maryland Innovation Initiative (MII) phase II grant from TEDCO
MycoMed Technologies wins a phase I STTR from NSF
MycoMed Technologies and Johns Hopkins win a phase I STTR award from the NIH
MycoMed Technologies wins Maryland Innovation Initiative (MII) phase I grant from TEDCO
MycoMed Technologies is founded by members of the Hopkins team and opens a laboratory at the University of Maryland BioPark
Hopkins team wins Maryland Innovation Initiative (MII) phase I grant from TEDCO
Hopkins team wins a Johns Hopkins Institute for Clinical and Translational Research award to accelerate the development of a urine diagnostic
Sponsors and Partners
